SCHEMBL1298660

SCHEMBL1298660

COc1ccc(CNc2nc(Nc3ccccc3)c3c(=O)n(C)ccc3n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.52
APP P05067 2/20 0.47
NPY5R Q15761 1/20 0.47
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MERTK Q12866 3/20 0.42
EHMT2 Q96KQ7 1/20 0.42
DNMT3A Q9Y6K1 1/20 0.42
HIF1A Q16665 1/20 0.42
CCNE2 O96020 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
HRH1 P35367 1/20 0.41
HRH4 Q9H3N8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12104008 0.89 APP (0.45) APPNPY5RMAPTNPSR1CYP1A2
SCHEMBL1298640 0.79 IRAK4 (0.47) NPY5RCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1298626 0.75 MAPT (0.39) APPNPY5RMAPTNPSR1L3MBTL1
SCHEMBL3289406 0.74 KCNH3 (0.69) SLC2A1APPNPY5RMAPTNPSR1
SCHEMBL12103986 0.74 MAPT (0.49) SLC2A1NPY5RMAPTNPSR1L3MBTL1
SCHEMBL1298350 0.73 EGFR (0.44) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1298216 0.71 IDH2 (0.56) APPNPY5RMAPTIRAK4
SCHEMBL1298790 0.71 NPY5R (0.51) NPY5RIRAK4
SCHEMBL1298474 0.70 CTNNB1 (0.52)
SCHEMBL2586993 0.70 SLC2A1 (0.81) SLC2A1APPMAPTNPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404677-B2 Kinase inhibitors GENOSCO (US) 2013-03-26 US claimed
US-20110269739-A1 KINASE INHIBITORS OSCOTEC, INC. (KR) 2011-11-03 US claimed
US-8404677-B2 Kinase inhibitors GENOSCO (US) 2013-03-26 US disclosed
US-8404677-B2 Kinase inhibitors GENOSCO (US) 2013-03-26 US disclosed
US-20110269739-A1 KINASE INHIBITORS OSCOTEC, INC. (KR) 2011-11-03 US disclosed
US-20110269739-A1 KINASE INHIBITORS OSCOTEC, INC. (KR) 2011-11-03 US disclosed
WO-2011053861-A1 KINASE INHIBITORS GENOSCO (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269739-A1 KINASE INHIBITORS JAK1, LCK, MAP3K20 SLC2A1 1572/4885APP 1317/4885NPY5R 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.